Search results
Showing 451 to 500 of 798 results for team work
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.
Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the ARCHITECT and ALINITY i Urine NGAL assays, BioPorto NGAL test and NephroCheck test.
Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal
Radiation dose monitoring software for medical imaging with ionising radiation (MIB127)
NICE has developed a medtech innovation briefing (MIB) on radiation dose monitoring software for medical imaging with ionising radiation .
In development Reference number: GID-TA11631 Expected publication date: TBC
Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088
Discontinued Reference number: GID-TA11702
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
Discontinued Reference number: GID-TAG432
Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.
Discontinued Reference number: GID-TAG379
Discontinued Reference number: GID-TAG426
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)
NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .
Discontinued Reference number: GID-TAG367
Prasterone for the treatment of systemic lupus erythematosus [ID392]
Discontinued Reference number: GID-TAG373
Discontinued Reference number: GID-TAG493
Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.
View recommendations for IPG383Show all sections
Sections for IPG383
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
Discontinued Reference number: GID-TA10148
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.
Discontinued Reference number: GID-TAG394
Discontinued Reference number: GID-TAG407
Discontinued Reference number: GID-TA10308
Discontinued Reference number: GID-TAG418
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]
Discontinued Reference number: GID-TAG440
Discontinued Reference number: GID-TAG422
In development Reference number: GID-TA11567 Expected publication date: TBC
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued Reference number: GID-TAG320
Discontinued Reference number: GID-TA10502
Discontinued Reference number: GID-TAG371
Vandetanib for the second line treatment of non-small cell lung cancer [ID46]
Discontinued Reference number: GID-TAG405
Discontinued Reference number: GID-TAG412
Discontinued Reference number: GID-TAG436
Discontinued Reference number: GID-TAG376
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Discontinued Reference number: GID-TAG300
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]
Discontinued Reference number: GID-TAG332
Temozolomide for the treatment of advanced and metastatic melanoma [ID316]
Discontinued Reference number: GID-TAG401
Discontinued Reference number: GID-TA11204
Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]
Discontinued Reference number: GID-TAG232
Venous thromboembolism - apixaban (acute medical illness) [ID310]
Discontinued Reference number: GID-TAG419
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
Discontinued Reference number: GID-TAG435
Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]
Discontinued Reference number: GID-TAG413
Discontinued Reference number: GID-TAG444
Discontinued Reference number: GID-HST10033
Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]
Discontinued Reference number: GID-TAG330
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]
In development Reference number: GID-TA11634 Expected publication date: TBC